These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34258507)

  • 1. Skeletal responses to romosozumab after 12 months of denosumab.
    McClung MR; Bolognese MA; Brown JP; Reginster JY; Langdahl BL; Shi Y; Timoshanko J; Libanati C; Chines A; Oates MK
    JBMR Plus; 2021 Jul; 5(7):e10512. PubMed ID: 34258507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
    McClung MR; Brown JP; Diez-Perez A; Resch H; Caminis J; Meisner P; Bolognese MA; Goemaere S; Bone HG; Zanchetta JR; Maddox J; Bray S; Grauer A
    J Bone Miner Res; 2018 Aug; 33(8):1397-1406. PubMed ID: 29694685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
    Cosman F; Crittenden DB; Ferrari S; Khan A; Lane NE; Lippuner K; Matsumoto T; Milmont CE; Libanati C; Grauer A
    J Bone Miner Res; 2018 Jul; 33(7):1219-1226. PubMed ID: 29573473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
    Lewiecki EM; Dinavahi RV; Lazaretti-Castro M; Ebeling PR; Adachi JD; Miyauchi A; Gielen E; Milmont CE; Libanati C; Grauer A
    J Bone Miner Res; 2019 Mar; 34(3):419-428. PubMed ID: 30508316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
    Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
    J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate.
    Lewiecki EM; Betah D; Humbert L; Libanati C; Oates M; Shi Y; Winzenrieth R; Ferrari S; Omura F
    J Bone Miner Res; 2024 May; 39(4):473-483. PubMed ID: 38477808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.
    McClung MR; Bolognese MA; Brown JP; Reginster JY; Langdahl BL; Maddox J; Shi Y; Rojeski M; Meisner PD; Grauer A
    Osteoporos Int; 2020 Nov; 31(11):2231-2241. PubMed ID: 32623487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study.
    Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y
    Bone; 2022 Sep; 162():116480. PubMed ID: 35787482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study.
    Adami G; Pedrollo E; Rossini M; Fassio A; Braga V; Pasetto E; Pollastri F; Benini C; Viapiana O; Gatti D
    JBMR Plus; 2024 Apr; 8(4):ziae016. PubMed ID: 38544922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
    Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
    Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension.
    Cosman F; Oates M; Betah D; Timoshanko J; Wang Z; Ferrari S; McClung MR
    J Bone Miner Res; 2024 Sep; 39(9):1268-1277. PubMed ID: 39041711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals.
    Cosman F; Libanati C; Deignan C; Yu Z; Wang Z; Ferrari S; Beck Jensen JE; Peris P; Bertoldo F; Lespessailles E; Hesse E; Cummings SR
    JBMR Plus; 2021 Nov; 5(11):e10546. PubMed ID: 34761149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study.
    Baek KH; Chung YS; Koh JM; Kim IJ; Kim KM; Min YK; Park KD; Dinavahi R; Maddox J; Yang W; Kim S; Lee SJ; Cho H; Lim SK
    Endocrinol Metab (Seoul); 2021 Feb; 36(1):60-69. PubMed ID: 33677928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.
    Horne AM; Mihov B; Reid IR
    Calcif Tissue Int; 2018 Jul; 103(1):55-61. PubMed ID: 29445836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One versus 2 years of alendronate following denosumab: the CARD extension.
    Tsai JN; Jordan M; Lee H; Leder BZ
    Osteoporos Int; 2024 Aug; ():. PubMed ID: 39112628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.
    Miyauchi A; Hamaya E; Yang W; Nishi K; Libanati C; Tolman C; Shimauchi J
    J Bone Miner Metab; 2021 Mar; 39(2):278-288. PubMed ID: 33057807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.